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Graphical Abstract
Highlights
d BET inhibitor suppresses TOPBP1 and WEE1 expression
d BET inhibitor and PARP inhibitor induce apoptosis in a
synergistic manner
d Combined BET and PARP inhibition causes mitotic
catastrophe
d BET and PARP inhibition synergize in suppressing BRCA1/2
wild-type ovarian tumors
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In Brief
Karakashev et al. show synergy of BET
bromodomain inhibition with PARP
inhibition in BRCA-proficient ovarian
cancers. This combination of inhibitors
can synergistically increase DNA damage
and cell-cycle checkpoint defects, which
allows cells to enter mitosis despite the
accumulation of DNA damage, ultimately
causing mitotic catastrophe.
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